Association of Signal Heterogeneity in the Hepatobiliary Phase of Gd‐ EOB ‐ DTPA ‐Enhanced MRI With Survival Outcomes and Tumor Microenvironment in Hepatocellular Carcinoma
Journal of Hepato-Biliary-Pancreatic Sciences · 2026-05 · 33 (5) · 352-360
DOI: 10.1002/jhbp.70085 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Hepato-Biliary-Pancreatic Sciences, online erschienen am 11.02.2026. Verfasst von Munetoshi Akaoka und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, The Jikei University School of Medicine, Tokyo, Japan. Hauptthemen laut MEDLINE: Liver Neoplasms, Carcinoma, Hepatocellular, Gadolinium DTPA, Tumor Microenvironment. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: Japan Society for the Promotion of Science, Takeda Science Foundation.
Abstract (Originalsprache)
Background
Hepatobiliary phase (HBP) findings on Gd‐EOB‐DTPA‐enhanced MRI (EOB‐MRI) have been proposed as biomarkers of hepatocellular carcinoma (HCC). However, the association between intratumor signal heterogeneity in HBP of EOB‐MRI and survival or tumor microenvironment remains unclear.
Methods
We retrospectively analyzed 167 patients who underwent hepatic resection for HCC. The coefficient of variation (CV) in HBP on preoperative EOB‐MRI was calculated as the standard deviation/mean of the intratumor signal intensity. Hyperintense area (HIA) was defined as tumor regions with signal intensity equal to or higher than the surrounding parenchyma. Associations of imaging‐defined heterogeneity (high CV with HIA) with survival and immune infiltration were evaluated.
Results
Multivariate analyses showed male, negative HBs‐antigen, elevated PIVKA‐II, multiple tumors, microvascular invasion, and high CV with HIA (all p < 0.05) were significant predictors of disease‐free survival, while negative HBs‐antigen, elevated PIVKA‐II, microvascular invasion, and high CV with HIA (all p < 0.05) were significant predictors of overall survival. High CV with HIA correlated with male ( p = 0.04), larger tumor size ( p < 0.01), multiple tumors ( p < 0.01), and less CD8 + T‐cell infiltration into tumor center ( p = 0.03) and invasive margin ( p = 0.048).
Conclusions
High CV with HIA in HBP of EOB‐MRI may serve as a novel prognostic imaging biomarker after resection and reflect an immune‐cold HCC microenvironment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, The Jikei University School of Medicine, Tokyo, Japan.
- Department of Radiology, The Jikei University School of Medicine, Tokyo, Japan.
ORCID-Profile: Koichiro Haruki, Kenei Furukawa, Michinori Matsumoto, Yoshihiro Shirai, Toru Ikegami
Förderung
- Japan Society for the Promotion of Science
- Takeda Science Foundation
Zitieren
APA
Akaoka, M., Haruki, K., Woo, J., Ohki, K., Furukawa, K., Onda, S., Tsunematsu, M., Matsumoto, M., Shirai, Y., & Ikegami, T. (2026). Association of Signal Heterogeneity in the Hepatobiliary Phase of Gd‐ EOB ‐ DTPA ‐Enhanced MRI With Survival Outcomes and Tumor Microenvironment in Hepatocellular Carcinoma. Journal of Hepato-Biliary-Pancreatic Sciences, 33(5), 352-360. https://doi.org/10.1002/jhbp.70085
Vancouver
Akaoka M, Haruki K, Woo J, Ohki K, Furukawa K, Onda S, et al. Association of Signal Heterogeneity in the Hepatobiliary Phase of Gd‐ EOB ‐ DTPA ‐Enhanced MRI With Survival Outcomes and Tumor Microenvironment in Hepatocellular Carcinoma. Journal of Hepato-Biliary-Pancreatic Sciences. 2026;33(5):352-360. doi:10.1002/jhbp.70085
BibTeX
@article{Akaoka2026,
author = {Akaoka, Munetoshi and Haruki, Koichiro and Woo, Jun and Ohki, Kazuyoshi and Furukawa, Kenei and Onda, Shinji and Tsunematsu, Masashi and Matsumoto, Michinori and Shirai, Yoshihiro and Ikegami, Toru},
title = {Association of Signal Heterogeneity in the Hepatobiliary Phase of Gd‐ EOB ‐ DTPA ‐Enhanced MRI With Survival Outcomes and Tumor Microenvironment in Hepatocellular Carcinoma},
journal = {Journal of Hepato-Biliary-Pancreatic Sciences},
year = {2026},
volume = {33},
number = {5},
pages = {352--360},
doi = {10.1002/jhbp.70085}
}
EUVIMED